PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290818
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290818
Transplant Diagnostics Market size was valued at USD 4,809.2 Million in 2022, expanding at a CAGR of 7.6% from 2023 to 2030.
The process of detecting and connecting both the cells and tissues of a donor as well as a recipient in transplant surgery is referred to as transplant diagnostics. It is an important element of the transplant procedure since the mutual compatibility of the donor and recipient is essential for a successful transplant. The purpose of transplant diagnostics is to reduce the possibility of rejection while also ensuring that the transplanted cell or organ works correctly in the recipient's system. The transplant process may begin after the donor and recipient have been matched. Following the transplant, the receiver will be constantly examined to verify that the donated tissue or organ is working well and that no symptoms of rejection exist. Continuous monitoring and testing are important to the transplant's long-term viability.
As the incidence of acute illnesses rises, so does the number of organ failures, boosting the need for transplant operations and boosting the transplant diagnostics industry. Organ transplantation is a complicated surgery, and the operation's success is dependent on the recipient's biological system accepting the donor's part. Transplantation diagnostic procedures are used to determine if an organ transplant will be acceptable. In accordance with the United Network for Organ Sharing, a non-profit organization located in the United States that handles organ transplantation in the country, the United States will see a record-breaking number of liver transplants in 2021. In 2021, 24,669 transplants of kidneys, 9,236 transplants of the liver, and 3,817 transplants of the heart were done. The transplant diagnostics industry is being driven by the growing need for diagnostic testing.
The Global Transplant Diagnostics Market is segmented on the basis of Product and Services, End-User, Technology, and Region.
The market is divided into three categories based on Product and Services: Instruments, Software and services, Reagents and consumables. Reagents and consumables dominate the market. The major feature of this market is the greater utilization prevalence of these items throughout all sectors and end-users, as well as higher replacement costs despite the lower costs. Companies of such diagnostic tools are using techniques such as reagents and consumable purchasing contracts. Furthermore, the frequent purchasing of reagents and consumables is a major element in promoting their adoption.
The market is divided into three categories based on End-User: Hospitals and transplants centers, Research laboratories and academic institutes, Commercial service providers. The hospitals and transplant centers dominate the market and are likely to maintain their dominance during the forecast period. Hospitals and transplant centers have grown dramatically, owing to increased demand for transplant commodities that include immunosuppressants, tissue goods, and also organ preservation procedures, as well as technological advancements. Rising incidence of acute diseases which lead to organ failure, as well as transplant businesses concentrating more on trademark security, are two more drivers driving the market growth.
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is likely to maintain its dominant position in the transplant diagnostics industry during the projected timeframe. Economies in the area, such as the USA and Canada, have well-funded groups, facilities, and government participation in generating money and awareness to encourage organ transplants for individuals. For example, the National Institute of Health estimates that funding for transplantation studies will be US $ 721 million, US $ 702 million, and US $ 735 million in 2020, 2021, and 2022, correspondingly. Increasing financing for transplantation studies will consequently lead to increased utilization of transplant diagnostics, driving market expansion in this area.
The global marketplace is extremely competitive, with just a few competitors fighting against one other. Some of the present possibilities and obstacles that businesses are anticipated to confront throughout the projected duration are advancements in technology concerning reagent efficiency, cost-effectiveness, physician's decision-making, increasing understanding, and adequate organ preservation infrastructure. The limitations of transplant diagnostic procedures such as serology-based as well as PCR-based HLA typing raise the total cost of goods. As a consequence, players are pursuing measures that include long-term agreements with diagnostic facilities and labs, as well as bulk purchasing discounts. Plexision, a biotechnology business established in the United States, has begun international operations by establishing its reference facility in Hyderabad, India. This laboratory will provide a full range of diagnostics for transplant patients. The company's proprietary personalized transplant diagnostic procedures used to predict resistance and viral infections are among these tests, as are medication-level surveillance, pharmacogenomics, and genetic evaluations.
In March 2023, Quest Diagnostics, the nation's top supplier of diagnostic imaging offerings, announced the launch of a complete package of advanced diagnostics as well as assistance services aimed at increasing access to laboratory testing for transplanting solid organs, human cells, and tissue.
The scope of this report covers the market by its major segments, which include as follows: